The Frazier Life Sciences team invests in and builds companies developing and commercializing novel therapeutics.

500+

Collective years of investing and operational experience

100

Portfolio companies

60

M&A and IPOs

29

FDA approved drugs since 2010

Selected M&A and IPOs

Acquired by AstraZeneca in 2016
IPO in 2014; Acquired by Roche in 2018
NASDAQ: IOVA
Acquired by AbbVie in 2019
IPO in 2019 (NASDAQ: MIRM)
IPO in 2019 (NASDAQ: PHAT)
Acquired by CutisPharma in 2019
Acquired by Allergan in 2016

Life Sciences News

Phathom Pharmaceuticals

Phathom Pharmaceuticals Announces Pricing of Initial Public Offering

Passage Bio

Passage Bio Closes $110 Million Series B Financing

Mavupharma

AbbVie Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma

Silvergate Pharmaceuticals

CutisPharma Announces Acquisition of Silvergate Pharmaceuticals, Name Change to Azurity Pharmaceuticals

View All News